DE3438821C2 - - Google Patents
Info
- Publication number
- DE3438821C2 DE3438821C2 DE3438821A DE3438821A DE3438821C2 DE 3438821 C2 DE3438821 C2 DE 3438821C2 DE 3438821 A DE3438821 A DE 3438821A DE 3438821 A DE3438821 A DE 3438821A DE 3438821 C2 DE3438821 C2 DE 3438821C2
- Authority
- DE
- Germany
- Prior art keywords
- osteoporosis
- solution
- administered
- rats
- dihydroxycholecalciferol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- FCKJYANJHNLEEP-XRWYNYHCSA-N (24R)-24,25-dihydroxycalciol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CC[C@@H](O)C(C)(C)O)C)=C\C=C1\C[C@@H](O)CCC1=C FCKJYANJHNLEEP-XRWYNYHCSA-N 0.000 claims description 22
- 208000001132 Osteoporosis Diseases 0.000 claims description 17
- 239000004046 24R,25-dihydroxy-cholecalciferol Substances 0.000 claims description 9
- 241000700159 Rattus Species 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 19
- 210000002303 tibia Anatomy 0.000 description 13
- 239000000126 substance Substances 0.000 description 10
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 150000004665 fatty acids Chemical class 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004100 Oxytetracycline Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 4
- 229960000625 oxytetracycline Drugs 0.000 description 4
- 235000019366 oxytetracycline Nutrition 0.000 description 4
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003262 anti-osteoporosis Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 231100001226 acute mammalian toxicity Toxicity 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000002956 ash Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 229920001225 polyester resin Polymers 0.000 description 2
- 239000004645 polyester resin Substances 0.000 description 2
- 229910052573 porcelain Inorganic materials 0.000 description 2
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 210000001694 thigh bone Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101100533310 Mus musculus Set gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 230000001944 accentuation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 229960002535 alfacalcidol Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58198454A JPS6089422A (ja) | 1983-10-24 | 1983-10-24 | 抗骨粗鬆症剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3438821A1 DE3438821A1 (de) | 1985-05-02 |
| DE3438821C2 true DE3438821C2 (en, 2012) | 1989-06-29 |
Family
ID=16391371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843438821 Granted DE3438821A1 (de) | 1983-10-24 | 1984-10-23 | Verwendung von 24,25-dihydroxycholecalciferol |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US4590184A (en, 2012) |
| JP (1) | JPS6089422A (en, 2012) |
| DE (1) | DE3438821A1 (en, 2012) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4020511A1 (de) * | 1989-07-28 | 1991-01-31 | Kureha Chemical Ind Co Ltd | Stabile pharmazeutische zusammensetzung enthaltend 24,25-dihydroxycholecalcipherol als einen wirkstoff |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61109721A (ja) * | 1984-11-01 | 1986-05-28 | Kureha Chem Ind Co Ltd | 骨粗しよう症における疼痛軽減剤 |
| IL74617A (en) * | 1985-03-15 | 1988-11-15 | Yeda Res & Dev | Compositions comprising a vitamin d derivative and method for the local treatment of bone fractures in animals |
| JPS6391323A (ja) * | 1986-10-03 | 1988-04-22 | Kureha Chem Ind Co Ltd | 抗尿路結石症剤 |
| JPS63166830A (ja) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | 老化防止剤 |
| JPS63166829A (ja) * | 1986-12-29 | 1988-07-11 | Kureha Chem Ind Co Ltd | 骨強度増強剤 |
| US5001118A (en) * | 1986-12-29 | 1991-03-19 | Kureha Kagaku Kogyo Kabushiki Kaisha | Method for preventing senescence and increasing bone mass |
| JPS63310828A (ja) * | 1987-06-10 | 1988-12-19 | Kureha Chem Ind Co Ltd | 経口骨折治癒促進剤 |
| US4997824A (en) * | 1987-07-22 | 1991-03-05 | Teva Pharmaceutical Industries Ltd. | Combination of cholecalciferol derivatives for the treatment of renal bone disease |
| IL89392A (en) * | 1988-03-23 | 1993-02-21 | Teva Pharmaceutical Ind Ltd Je | Compositions for the treatment of osteoporosis in humans comprising 24, 25-dihydroxy-vitamin d3 |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| JPH04129306U (ja) * | 1991-05-22 | 1992-11-26 | 三菱自動車工業株式会社 | サスペンシヨンアームの支持構造 |
| JPH04130507U (ja) * | 1991-05-27 | 1992-11-30 | 三菱自動車工業株式会社 | トルクロツドの取付構造 |
| KR960013798B1 (ko) * | 1992-04-24 | 1996-10-10 | 재단법인 한국전자통신연구소 | 평면 도파로형 공간 스위치 |
| AU666529B2 (en) * | 1992-04-24 | 1996-02-15 | Wisconsin Alumni Research Foundation | Method of treating osteoporosis with 1 alpha, 24 (R)-dihydroxy-22 (E)-dehydro-vitamin D3 |
| US5354743A (en) * | 1992-09-15 | 1994-10-11 | Thys Jacobs Susan | Method for the treatment of premenstrual syndrome with vitamin D |
| KR950000153A (ko) * | 1993-06-21 | 1995-01-03 | 아라끼 타다시 | 신성골이영양증(Renal Osteodystrophy)의 골질량감소 억제제 |
| JP2684587B2 (ja) * | 1993-06-21 | 1997-12-03 | 呉羽化学工業株式会社 | 腎性骨異栄養症における骨量減少抑制剤 |
| US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
| JPH11257360A (ja) | 1998-01-07 | 1999-09-21 | Nippon Seiko Kk | シールリング付転がり軸受及び自動車用変速機 |
| AU2004230950C1 (en) * | 2003-04-09 | 2011-08-04 | Koppers Performance Chemicals Inc. | Micronized wood preservative formulations |
| MXPA05013850A (es) | 2003-06-17 | 2006-05-17 | Phibro Tech Inc | Conservador particulado para madera y metodo para producir el mismo. |
| US20050252408A1 (en) | 2004-05-17 | 2005-11-17 | Richardson H W | Particulate wood preservative and method for producing same |
| BRPI0518154A (pt) | 2004-10-14 | 2008-11-04 | Osmose Inc | composição conservante de madeira, e, método para conservar um produto de madeira |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3715374A (en) * | 1972-05-05 | 1973-02-06 | Wisconsin Alumni Res Found | 24,25-dihydroxycholecalciferol |
| JPS55136229A (en) * | 1979-04-10 | 1980-10-23 | Teijin Ltd | Adjustment of bone metabolism in warm-blooded animal and drug for it |
| JPS55139320A (en) * | 1979-04-16 | 1980-10-31 | Teijin Ltd | Bone metabolism regulator |
| US4338250A (en) * | 1981-04-27 | 1982-07-06 | Wisconsin Alumni Research Foundation | 1-Hydroxylation process |
| US4456553A (en) * | 1982-05-07 | 1984-06-26 | Teijin Limited | Vitamin D3 derivatives, process for preparation thereof, and antigens comprising said derivatives to be used for preparation of antibodies for immunochemical assay and antibodies prepared therefrom |
-
1983
- 1983-10-24 JP JP58198454A patent/JPS6089422A/ja active Granted
-
1984
- 1984-10-18 US US06/662,044 patent/US4590184A/en not_active Expired - Lifetime
- 1984-10-23 DE DE19843438821 patent/DE3438821A1/de active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4020511A1 (de) * | 1989-07-28 | 1991-01-31 | Kureha Chemical Ind Co Ltd | Stabile pharmazeutische zusammensetzung enthaltend 24,25-dihydroxycholecalcipherol als einen wirkstoff |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3438821A1 (de) | 1985-05-02 |
| US4590184A (en) | 1986-05-20 |
| JPS6089422A (ja) | 1985-05-20 |
| JPH0132208B2 (en, 2012) | 1989-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3438821C2 (en, 2012) | ||
| DE69910559T2 (de) | Neue fettanaloge zur behandlung der fettleibigkeit | |
| DE3338995C2 (en, 2012) | ||
| DE602004010531T2 (de) | Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma | |
| DE2810918A1 (de) | Taurin-derivate mit neuromuskulaerer wirksamkeit, verfahren zu deren herstellung und arzneimittel | |
| DE69528291T2 (de) | Nicht-beta oxidierbare fettsäureanaloge,deren verwendung als therapeutisch wirksame medikamente sowie deren herstellung | |
| DE69129115T2 (de) | Neues verfahren zur behandlung von depression | |
| DE69431965T2 (de) | Wirkstoff gegen fettsucht | |
| CH644518A5 (de) | Pharmazeutisches praeparat zur regulierung des knochenmetabolismus. | |
| DE3781667T2 (de) | Verwendung von 24,25-dihydroxycholecalciferol zur verhuetung des knochenalterns. | |
| DE3035494A1 (de) | Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels | |
| EP0345247A2 (de) | Verwendung von monosubstituierten selenorganischen Verbindungen zur Herstellung eines Arzneimittels sowie daraus hergestelltes Arzneimittel und Verfahren zu seiner Herstellung | |
| DE2507635C2 (en, 2012) | ||
| DE69501421T2 (de) | Hematetrenome Derivat als antiarteriosklerotisches Mittel | |
| DE2660486C2 (de) | Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel | |
| DE3874900T2 (de) | Wirkstoff mit die nierenfunktion verbesserndem und diuretischem effekt und verwendung eines darin enthaltenen benzothiazepin-derivates. | |
| DE3125512A1 (de) | L-arginin-d,l-pyroglutamat als auf neuroedokrinem gebiet wirksames mittel | |
| DE2126533A1 (de) | Verfahren zur Herstellung pharma zeutischer Zubereitungen | |
| DE19810999A1 (de) | Verwendung von Sphingosin, Sphingosin-1-Phosphat, Sphingosin-1-Phosphat-Derivaten und/oder deren Gemischen zur Behandlung von entzündlichen Hautkrankheiten | |
| DE69022206T2 (de) | Aldosereduktasehemmer enthaltende Zubereitungen zur Behandlung von Geschwüren. | |
| DE2625053C3 (de) | Arzneimittel zur Kontrolle von Leberkrankheiten | |
| EP0086476B1 (de) | Verwendung von Cholecalciferolderivaten | |
| DE69413544T2 (de) | Reduzierte absorption von fettsäuren | |
| DE2037942A1 (de) | Arzneimittel zur Verhinderung der Atheroklerose und des Wiederauftretens kardiocaskulärer Anfälle bei atherosklerotischen Säugetieren | |
| EP0472033A2 (de) | 3,5-Diiod-L-Thyronin zur TSH-Suppression und Behandlung von Struma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8128 | New person/name/address of the agent |
Representative=s name: KADOR, U., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 800 |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |